| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sarah Gilbert | Q30513802 |
| George M Warimwe | Q90348796 | ||
| P2860 | cites work | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA | Q24289279 |
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe | Q24289281 | ||
| A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity | Q28727030 | ||
| Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs | Q28768041 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Emerging and reemerging of filoviruses. | Q40674892 | ||
| An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels | Q40867301 | ||
| Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study | Q41088356 | ||
| Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors | Q42107571 | ||
| Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. | Q51628462 | ||
| Rift valley fever | Q71188972 | ||
| Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics | Q33357041 | ||
| Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study | Q33409373 | ||
| Geographic distribution of MERS coronavirus among dromedary camels, Africa | Q33950974 | ||
| Epidemiologic and Clinical Aspects of a Rift Valley Fever Outbreak in Humans in Tanzania, 2007 | Q34034096 | ||
| Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. | Q34059153 | ||
| Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge | Q34437167 | ||
| Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial | Q34488529 | ||
| Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial | Q34522696 | ||
| Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections | Q35557184 | ||
| Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013-2014. | Q35897083 | ||
| Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever | Q36548980 | ||
| Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. | Q37664563 | ||
| Pathogenesis of Middle East respiratory syndrome coronavirus | Q38258027 | ||
| Rift Valley Fever: An Emerging Mosquito-Borne Disease | Q38776944 | ||
| Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study | Q38808444 | ||
| Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. | Q39866377 | ||
| Vaccination for the control of Rift Valley fever in enzootic and epizootic situations | Q40247216 | ||
| A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults | Q40344955 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| Creative Commons Attribution 4.0 International | Q20007257 | ||
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 35 Pt A | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Adenoviridae | Q193447 | ||
| infection | Q166231 | ||
| emerging communicable disease | Q609748 | ||
| disease outbreak | Q3241045 | ||
| genetic vector | Q427389 | ||
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 4461-4464 | |
| P577 | publication date | 2017-05-30 | |
| 2017-08-16 | |||
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology | |
| P478 | volume | 35 |
| Q64230886 | An updated roadmap for MERS-CoV research and product development: focus on diagnostics |
| Q56971688 | Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models |
| Q47570091 | Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic |
| Q63740056 | Emerging viruses and current strategies for vaccine intervention |
| Q61818478 | From SARS to MERS, Thrusting Coronaviruses into the Spotlight |
| Q64374679 | Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components |
| Q51347385 | Vaccinology in the 21st century-The 10th Annual Vaccine Congress. |
Search more.